Natera Stock Expands into Cancer Blood Testing
To say it’s been a tough year for retail investors would be an understatement. That’s especially true for technology stocks, with the Nasdaq down 35% for the year compared to about a 20% drop for the S&P 500. Interestingly, biotech stocks haven’t done as bad, based on the broad NASDAQ Biotechnology Index (NBI), which currently […]